Icahn School of Medicine names new dean of translational research, therapeutic innovation
Click Here to Manage Email Alerts
Miriam Merad, MD, PhD, has been appointed the new dean of translational research and therapeutic innovation at Mount Sinai’s Icahn School of Medicine.
Merad, also a Mount Sinai professor in cancer immunology, will continue to serve as founding chair of the department of immunology and immunotherapy, director of the Marc and Jennifer Lipschultz Precision Immunology Institute, and director of the Human Immune Monitoring Center, according to a press release.
She is a pioneer in the field of oncology who has made significant contributions to the understanding of the functions of innate immune cells in cancer and inflammatory diseases, according to the release. As dean, Merad will elevate early clinical trials, streamline the clinical process, cultivate a culture of mechanistic clinical trials throughout the institution and forge stronger partnerships with both the pharmaceutical and biotech sectors.
“I am honored to have the opportunity to continue to expand Mount Sinai’s mission of transforming medicine,” Merad said in the release. “We are witnessing an unparalleled era in medical history, marked by technological breakthroughs that have revolutionized our comprehension of disease mechanisms, molecular response to treatments, and the creation of innovative therapeutic approaches. In my new role, I will strive to enhance Mount Sinai’s proficiency in these critical areas, reinforcing our dedication to advancing health on a global scale.”
Merad is also a fellow of the American Association for Cancer Research and a member of the Academy of Immuno-Oncology. In 2009, she founded the Mount Sinai Human Immune Monitoring Center, which is recognized today as a leader in identifying novel therapeutic targets, playing a critical role in the fight against cancer and inflammatory diseases, according to the release.
She also made notable strides in understanding dendritic cells, which govern adaptive immunity.
“Dr. Merad’s vision transformed our understanding of the role of inflammation in diseases and advanced innovative immunotherapy strategies on campus and beyond,” Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai and president for Academic Affairs of the Mount Sinai Health System, said in the release. “She has elevated Mount Sinai as a premier destination for unraveling the mysteries of the human immune system.”
Read more about
Click Here to Manage Email Alerts